Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 13/20 | 0.83 |
| ▸ | DNMT3B | Q9UBC3 | 5/20 | 0.79 |
| ▸ | FPR2 | P25090 | 6/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996532 | 1.00 | DNMT1 (0.83) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL536436 | 1.00 | DNMT1 (0.83) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL536435 | 1.00 | DNMT1 (0.83) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL536396 | 0.85 | DNMT1 (0.67) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL15996543 | 0.85 | DNMT1 (0.67) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL536395 | 0.85 | DNMT1 (0.67) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL536055 | 0.84 | DNMT1 (0.76) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL536054 | 0.84 | DNMT1 (0.76) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL15996524 | 0.84 | DNMT1 (0.76) | DNMT1DNMT3BFPR2ADRB1 | |
| SCHEMBL536455 | 0.84 | DNMT1 (0.75) | DNMT1DNMT3BFPR2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822146-B2 | Derivatization of biomolecules by covalent coupling of non-cofactor compounds using methyltransferases | VILNIUS UNIVERSITY (LT) | 2014-09-02 | — | — | US | disclosed |
| EP-2414528-B1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | UNIV VILNIUS (LT) | 2014-05-07 | — | — | EP | disclosed |
| US-20120094280-A1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2012-04-19 | — | — | US | disclosed |
| US-20120094280-A1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2012-04-19 | — | — | US | disclosed |
| WO-2010115846-A1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094280-A1 | DERIVATIZATION OF BIOMOLECULES BY COVALENT COUPLING OF NON-COFACTOR COMPOUNDS USING METHYLTRANSFERASES | EZH1, DOHH, BHMT2 | DNMT1 9/4885DNMT3B 14/4885FPR2 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.